
Last updated: 2026-10-01 09:12:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Latigo Biotherapeutics, Inc. (LTGO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.88, with a market capitalisation of $1.20B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.19 to $25.93. This page covers its latest market performance, valuation, price trends and company information.
$1.20B | |
$17.88 | |
$25.93 | |
$16.19 | |
$16.70 | |
-- | |
391.32K | |
-- | |
$25.93 | |
$16.19 | |
-- | |
-- |
Latigo Biotherapeutics, Inc. (LTGO) is trading at $17.88 in pre-market trading as of 2026-10-01 08:10:00, up 7.04% ($1.18) from the previous close of $16.70
Pre-market trading shows how investors are pricing LTGO before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Latigo Biotherapeutics, Inc. (LTGO) moved from $20.82 to $17.88, representing a decline of 14.14% ($2.94).
The stock traded between $16.19 and $21.33 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 428.52 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 17.3%
LTGO is currently trading at $17.88, placing it 17.3% of the way from its 52-week low of $16.19 to its 52-week high of $25.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Latigo Biotherapeutics, Inc. (LTGO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.